Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
暂无分享,去创建一个
James S Babb | Eric E Sigmund | J. Babb | E. Sigmund | L. Moy | S. Kim | K. Jhaveri | F. Ponzo | A. Melsaether | Komal Jhaveri | A. Pujara | R. Raad | Roy A Raad | Sungheon G Kim | Amy N Melsaether | Akshat C Pujara | Fabio D Ponzo | Kristine M Pysarenko | Linda A Moy | Kristine Pysarenko | Amy N. Melsaether
[1] G. V. von Schulthess,et al. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. , 2014, Radiology.
[2] R. Sievert,et al. Book Reviews : Recommendations of the International Commission on Radiological Protection (as amended 1959 and revised 1962). I.C.R.P. Publication 6. 70 pp. PERGAMON PRESS. Oxford, London and New York, 1964. £1 5s. 0d. [TB/54] , 1964 .
[3] D. Loeffelbein,et al. Performance of Whole-Body Integrated 18F-FDG PET/MR in Comparison to PET/CT for Evaluation of Malignant Bone Lesions , 2014, The Journal of Nuclear Medicine.
[4] M. Senda,et al. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors , 2008, Annals of nuclear medicine.
[5] G. Brix,et al. Radiation exposure of patients undergoing whole-body FDG-PET/CT examinations , 2014, Nuklearmedizin.
[6] Martin G Mack,et al. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data. , 2004, Radiology.
[7] A. Loft,et al. Contrast-enhanced FDG-PET/CT vs. spio-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation , 2007, Acta radiologica.
[8] Thomas Beyer,et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] W. Huda,et al. CT effective dose per dose length product using ICRP 103 weighting factors. , 2011, Medical physics.
[10] Sebastian Fürst,et al. PET/MR Imaging in the Detection and Characterization of Pulmonary Lesions: Technical and Diagnostic Evaluation in Comparison to PET/CT , 2014, The Journal of Nuclear Medicine.
[11] C. Claussen,et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study. , 2012, Radiology.
[12] Willi A Kalender,et al. The effect of angular and longitudinal tube current modulations on the estimation of organ and effective doses in x-ray computed tomography. , 2009, Medical physics.
[13] W. Meyers,et al. Liver metastases from breast cancer: long-term survival after curative resection. , 2000, Surgery.
[14] Felix Nensa,et al. Whole-body [18F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results , 2014, European Radiology.
[15] H. Chandarana,et al. Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy , 2016, Journal of magnetic resonance imaging : JMRI.
[16] C. Mader,et al. Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[17] Pek-Lan Khong,et al. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. , 2009, Radiology.
[18] Gerald Q. Maguire,et al. Role of Fusion of Prone FDG‐PET and Magnetic Resonance Imaging of the Breasts in the Evaluation of Breast Cancer , 2010, The breast journal.
[19] Sergios Gatidis,et al. Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. , 2014, Radiology.
[20] Felix Nensa,et al. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[21] U. Schick,et al. Breast cancer brain metastases - A 12 year review of treatment outcomes. , 2015, Breast.
[22] B R Rosen,et al. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients , 2015, British Journal of Cancer.
[23] M. Wyss,et al. [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer , 2003, Journal of Cancer Research and Clinical Oncology.
[24] D. Groheux,et al. Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer , 2012, Journal of the National Cancer Institute.
[25] Walter Huda,et al. Converting dose-length product to effective dose at CT. , 2008, Radiology.
[26] Y Maruyama,et al. A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.
[27] J. Babb,et al. Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ‐based Comparison With PET/CT , 2016, The breast journal.
[28] M. Phelps,et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] A. Alavi,et al. Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer , 2006, Breast Cancer Research and Treatment.
[30] A. Bleyer,et al. Breast cancer before age 40 years. , 2009, Seminars in oncology.
[31] M. J. Fusselman,et al. Brain metastases from non-central nervous system tumors: evaluation with PET. , 1993, Radiology.
[32] A. Drzezga,et al. First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.
[33] A. Jena,et al. imultaneous whole-body 18 F-FDG PET-MRI in primary staging of reast cancer : A pilot study , 2014 .
[34] Jack Valentin,et al. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. , 2007, Annals of the ICRP.
[35] K. Eichler,et al. Breast cancer metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data. , 2004, Radiology.
[36] Andrea Soricelli,et al. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. , 2014, European journal of radiology.
[37] I. Cho,et al. Evaluation of Dixon Sequence on Hybrid PET/MR Compared with Contrast-Enhanced PET/CT for PET-Positive Lesions , 2014, Nuclear Medicine and Molecular Imaging.
[38] Raymond R Tubbs,et al. Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.